Translational Medicine
Clinical Pharmacology & Therapeutics (2007) 81, 595–599. doi:10.1038/sj.clpt.6100128; published online 21 February 2007
Application of Pharmacogenomic Strategies to the Study of Drug-induced Birth Defects
- 1Department of Pediatrics, Section of Developmental Pharmacology and Experimental Therapeutics, Children's Mercy Hospitals and Clinics, Kansas city, Missouri, USA
- 2Slone Epidemiology Center at Boston University, Boston, Massachusetts, USA
Correspondence: JS Leeder, (sleeder@cmh.edu)
Abstract
Approximately 3% of all infants are born with one or more major birth defects, resulting in >150,000 affected babies each year in the US alone.1 At present, birth defects account for more than 21% of all infant deaths, making them the leading cause of infant mortality.2 Although the etiology and determinants of individual susceptibility are largely unknown for most congenital malformations, pharmacogenomic analyses offer promise for the future.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Give the embryo a chanceNature Medicine News and Views (01 Jan 1997)
Therapy Are TNF inhibitors safe in pregnancy?Nature Reviews Rheumatology News and Views (01 Apr 2009)
